Dr. Bibha Choudhary
Research Focus Key Words
Pharmacogenomics, Cancer Biology, Rare disease, Therapeutics.
Dr. Bibha Choudhary received her PhD from BHU, Varanasi. Subsequently she did post-doctoral work at the Institute for Genetic Medicine, USC, Los Angeles. She has taught at the Manipal Institute of Regenerative Medicine, Manipal University. She joined IBAB in April 2011. Her lab focuses on understanding the molecular basis of cancer and rare diseases using Next Generation Sequencing approaches. Her lab is also involved in discovering novel cancer treatments and biomarkers.
PhD: BHU, Varanasi.
Postdoctoral Research: Genetic Medicine, USC, Los Angeles.
Manipal Institute of Regenerative Medicine, Manipal University.
Research Interest Profile
of synthetic compounds for anti-cancer properties and understanding their mode
One area of research in Dr. Bibha Choudhary’s lab is the screening of chemically synthesized as well as naturally derived compounds for anti-cancer properties, and the study of their mode of action at the molecular level. These studies have identified promising candidates, some of which are currently being investigated in vivo. The group is also exploring target specific, small molecule inhibiors against proteins which are upregulated specifically in cancers. Additionally, Dr. Bibha is interested in understanding global gene regulation by anti-cancer compounds using transcriptomics and miRomics approaches.
of Cancer and Rare diseases
Dr. Bibha Choudhary’s lab is interested in correlating phenotype to genotype. It is interested in studying the impact of variation in the genome on disease susceptibility in rare diseases. Multiple approaches including genomics, epigenomics, transcriptomics, and downstream molecular and cell biology experiments are used to decipher disease mechanisms, in breast cancer, ovarian cancer, head and neck cancer, prostate cancer and AML in Indian patient cohorts.
- Dr. Subha Srinivasan, Faculty Scientist, IBAB, Bengaluru
- Prof. Sathees C. Raghavan, Professor, Deptartment of Biochemistry, Indian Institute of Science, Bengaluru
- Prof. N. Yathindra, Biocon Chair, IBAB, Bengaluru
- Prof. Subhas S. Karki, Professor, Department of Pharmaceutical Chemistry, KLE University, Bengaluru
- Dr. Manjula Das, Principal Investigator, Mazumdar Shaw Center for Translational Research, Bengaluru
- Dr. K. Mantelingu, Assistant Professor, DOS in Chemistry, University of Mysore, Mysuru
- Dr. Sharath Kumar, Assistant Professor, DOS in Chemistry, University of Mysore, Mysuru
- Dr. Ananda H, Scientific Officer, Central Research Laboratory- Adichunchangari institute of Molecular Medicine, Bengaluru
- Dr. Jayanti Thumsi, Consultant Breast Surgeon, Sparsh Hospital, Yeshwanthpur, Bengaluru
- Dr. Sachin Jadhav, Hematologist, Forstis Hospital, Bannerghatta, Bengaluru
- Dr. Raghunath SK, Medical Oncologist, HCG Hospital, Sampangiram Nagar, Bengaluru
- Dr. Vishal Rao, Surgical Oncologist- Head and Neck, HCG hospital, Sampangiram Nagar, Bengaluru
- Dr. Ramesh C, Professor, Department of Epidemiology and Biostatistics, Kidwai Memorial Institute of Oncology, Bengaluru
- Dr. Kalaimathi Murugesan, Principal Investigator, IBAB, Bengaluru
Group Members Post Doctrol Fellows
- Febina R
- Raksha Rao K
- Suran R Nambisan (joint student)
- Jinsha K
- Snehal Nirgude
- Meghana Manjunath
- Sagar Desai
Junior Research Fellows
MSc Dissertation Students
- Amruta Kulkarni (Msc 07 student)
- Nabiha Sadique (Msc 07 student)
- Shivangi Verma (Msc 07 student)
- Sameesh Kher (Msc 07 student)
Select publications are as follows:
- Sunil M, Hariharan AK, Nayak S, Gupta S, Nambisan SR, Gupta RP, Panda B, Choudhary B, Srinivasan S.
The draft genome and transcriptome of Amaranthus hypochondriacus: a C4 dicot producing high-lysine edible pseudo-cereal. DNA Res. 2014 Dec;21(6):585-602. doi: 10.1093/dnares/dsu021.
- Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, Kumar S, Pandey M, Singh RK, Ray P, Natarajan R, Kelkar M, De A, Choudhary B, Raghavan SC.
An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21;151(7):1474-87. doi: 10.1016/j.cell.2012.11.054
- Iyer D, Vartak SV, Mishra A, Goldsmith G, Kumar S, Srivastava M, Hegde M, Gopalakrishnan V, Glenn M, Velusamy M, Choudhary B, Kalakonda N, Karki SS, Surolia A, Raghavan SC.
Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain. FEBS J. 2016 Sep;283(18):3408-37. doi: 10.1111/febs.13815.
- Hariharan N, Ravi S, Pradeep BE, Subramanyam KN, Choudhary B, Srinivasan S, Khanchandani P.
A novel loss-of-function mutation in HACE1 is linked to a genetic disorder in a patient from India. Hum Genome Var. 2018 Feb 8;5:17061. doi: 10.1038/hgv.2017.61. ECollection 2018.
- Gopalakrishnan V, Dahal S, Radha G, Sharma S, Raghavan SC, Choudhary B.
Characterization of DNA double-strand break repair pathways in diffuse large B cell lymphoma. Mol Carcinog. 2019 Feb;58(2):219-233. doi: 10.1002/mc.22921.